Search results
Results from the WOW.Com Content Network
Proctalgia fugax is a severe, episodic pain in the rectum and anus, often misinterpreted as a need to defecate. It can be caused by cramping of the levator ani muscle, particularly in the pubococcygeal part, and may be prevented or treated by various methods such as galvanic stimulation, diazepam, or botulinum toxin injections.
Other options for strabismus management are vision therapy and occlusion therapy, corrective glasses (or contact lenses) and prism glasses, and strabismus surgery. The effects that are due only to the toxin itself (including the side effects) generally wear off within 3 to 4 months.
Strabismus is a vision disorder in which the eyes do not align properly when looking at an object. It can result in double vision, amblyopia, and psychosocial difficulties. Learn about the symptoms, diagnosis, treatment, and history of strabismus.
Dogs with von Willebrand Disease can have a range of symptoms. Some dogs with the mild form of the disease can be asymptomatic for much of their lives until another disease pushes them into ...
A prism cover test is a method to measure strabismus, or eye misalignment, by using prism bars and an occluder. It involves performing an alternate cover test with different prism strengths until the deviation is neutralised.
CPEO stands for chronic progressive external ophthalmoplegia, a condition that affects the ability to move the eyes and eyebrows. It is often associated with other symptoms of mitochondrial disease, such as muscle weakness, hearing loss, and retinal abnormalities.
Intestinal pseudo-obstruction is a condition where the intestine becomes obstructed without any physical blockage. It can cause abdominal pain, nausea, vomiting, constipation, and other complications. Learn about the causes, symptoms, diagnosis, and treatment of this disorder.
Bedinvetmab is a canine monoclonal antibody that targets nerve growth factor and is used to control pain associated with osteoarthritis in dogs. It was approved in the EU in 2020 and in the US in 2023, but faced controversy over its efficacy claims.